Navigation Links
New cell therapy a promising atherosclerosis treatment
Date:3/1/2011

Researchers at Karolinska Institutet have shown in a new study on mice, that cell therapy can be used to reverse the effect of 'bad' LDL cholesterol and reduce the inflammation that leads to atherosclerosis. The new cell therapy, which is presented in the prestigious scientific journal Circulation, can open the way for new therapies for stroke and myocardial infarction if the results prove translatable to humans.

Atherosclerosis is a chronic inflammation of the blood vessels. Cholesterol is transported in the blood in particles called LDL ('bad' cholesterol) that can accumulate in the vessel walls. This triggers the body's immune system to react against LDL, which then cause inflammation in the vessels, and eventually thrombus formation. If such a thrombus forms in the coronary artery, the patient suffers a myocardial infarction; if it forms in the brain, a stroke can result.

The research group, under the direction of Professor Gran K Hansson at the Centre for Molecular Medicine, have developed a cell therapy that selectively dampens vascular inflammation induced by LDL. The therapy makes use of dendritic cells, which are characterized by a high degree of plasticity that renders them amenable to manipulation.

"With the appropriate treatment, dendritic cells can be made to inhibit rather than aggravate the inflammation around the LDL particles in the blood vessels," says Dr Andreas Hermansson, one of the researchers conducting the study. "A major advantage of this is that we can devise a treatment for vascular diseases that is highly specific."

The mouse studies now presented in Circulation have demonstrated substantial protective effects of the treatment, with a reduction of the atherosclerosis process of up around 70 percent. Last year, the researchers published results showing that antibodies recognizing the receptors that drive the immune reaction have protective effects, and now the same group is presenting a cell therapy that is at least as efficacious. It is hoped that this will pave the way for a completely new generation of selective anti-inflammatory therapies for cardiovascular disease.

"Treatments of atherosclerosis have traditionally targeted blood lipids, but a large proportion of treated patients still suffer life-threatening infarctions and stroke," says Professor Hansson. "We're now looking at the possibility of getting to the root of the problem and re-set, so to speak, the immune system's reaction to LDL, since it often has devastating consequences."


'/>"/>

Contact: Katarina Sternudd
katarina.sternudd@ki.se
46-852-483-895
Karolinska Institutet
Source:Eurekalert

Related biology news :

1. Why chemotherapy causes more infertility in women than in men
2. First-of-its-kind study shows benefits of electrical stimulation therapy for people paralyzed by spinal cord injury
3. Drug therapy shows significant benefit in treating a leading cause of childhood blindness
4. U of Alberta researcher discovers potential cancer therapy target
5. UTHealth, Athersys preclinical research on stem cell therapy for stroke presented at AHA conference
6. Photodynamic therapy against cancer
7. A loose grip provides better chemotherapy
8. Early tests find nanoshell therapy effective against brain cancer
9. New anti-HIV gene therapy makes T-cells resistant to HIV infection
10. Caffeine energizes cells, boosting virus production for gene therapy applications
11. Nanodisk gene therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... News solutions for biometrics, bag drop and ... ... to 16 March, Materna will present its complete end-to-end passenger ... is a real benefit for passengers. To accelerate the whole ... touch point solutions to take passengers through the complete integrated ...
(Date:2/24/2017)... BARCELONA, Spain , Feb. 24, 2017  EyeLock LLC, ... will demonstrate its elite iris biometric solution on ... with X16 LTE at Mobile World Congress ... in Qualcomm,s Booth in Hall 3, Stand ... contains the Qualcomm Haven™ security platform—a combination ...
(Date:2/16/2017)... 2017  Genos, a community for personal genetic ... received Laboratory Accreditation from the College of American ... laboratories that meet stringent requirements around quality, accuracy ... "Genos is committed to maintaining the ... honored to be receiving CAP accreditation," said ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... 23, 2017 Kineta, Inc., a biotechnology ... therapies in immuno-oncology, today announced the discovery and ... compounds that activate interferon response factor 3 (IRF3) ... immune-mediated tumor regression in a murine colon carcinoma ... demonstrated complete tumor regression to initial drug treatment ...
(Date:3/23/2017)... Orleans, La. (PRWEB) , ... March 23, 2017 ... ... real-time, industrial monitoring solutions, today announced the hire of Dr. Sigmund “Sig” Floyd ... APMT customer applications, strategic partnerships and joint development activities. , “Dr. Floyd’s career ...
(Date:3/22/2017)... , March 22, 2017 Good Start Genetics, ... has eclipsed the 130 million covered lives mark through ... of Texas . With newly signed ... continues to enjoy strong payor acceptance based on the ... programs and genetic counseling, its industry-leading customer care and ...
(Date:3/22/2017)... - FACIT announced a seed stage investment in ... created by FACIT focused on developing a portfolio ... non-dilutive capital, achieves a targeted $3.0M financing for ... to accelerate the nomination of a candidate drug ... a strategic partnership for clinical trials in patients ...
Breaking Biology Technology: